What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the proportion of patients with plaque psoriasis treated with different biologics who achieve the treatment goals and acceptable responses of the National Psoriasis Foundation (NPF) at week 12. Specifically, the NPF recommends evaluating the treatment response of patients at week 12 after the start of treatment. The target response is defined as the affected body surface area (BSA) ≤ 1%, and the acceptable response is defined as BSA ≤ 3% or BSA improvement ≥ 75%. This paper evaluates the differences in the effectiveness of these treatment regimens in achieving NPF goals and acceptable responses by comparing the performance of patients treated with ixekizumab (IXE) and other biologics (such as etanercept, guselkumab, ustekinumab, etc.) in clinical trials and real - world studies. ### Research Background - **Treatment Goals**: The NPF recommends evaluating the treatment response of patients at week 12 after the start of treatment. The target response is BSA ≤ 1%, and the acceptable response is BSA ≤ 3% or BSA improvement ≥ 75%. - **Research Purpose**: This paper aims to compare the proportion of patients with plaque psoriasis treated with ixekizumab (IXE) and other biologics who achieve the NPF goals and acceptable responses at week 12. ### Methods - **Research Design**: This paper includes data from four head - to - head randomized controlled trials (UNCOVER - 2, UNCOVER - 3, IXORA - R, IXORA - S) and one real - world prospective observational study (PSoHO). - **Participants**: Each study includes patients with moderate - to - severe plaque psoriasis who receive treatment with IXE or other biologics. - **Treatment Regimens**: - **UNCOVER - 2 and UNCOVER - 3**: Patients were randomly assigned to receive IXE every two weeks (Q2W), etanercept 50mg twice a week, or placebo. - **IXORA - R**: Patients were randomly assigned to receive IXE or guselkumab. - **IXORA - S**: Patients were randomly assigned to receive IXE or ustekinumab. - **PSoHO**: Includes adult patients from 23 countries who start or switch biologic treatment in routine medical care. ### Results - **Clinical Trial Data**: - **Target Response**: In the four head - to - head clinical trials, the proportion of patients in the IXE group who achieved BSA ≤ 1% at week 12 was significantly higher than that in the other biologic groups. - **Acceptable Response**: In the four head - to - head clinical trials, the proportion of patients in the IXE group who achieved BSA ≤ 3% or BSA improvement ≥ 75% at week 12 was significantly higher than that in the other biologic groups. - **Real - World Data (PSoHO)**: - **Target Response**: In the PSoHO study, the proportion of patients using anti - IL - 17A biologics (IXE or secukinumab) who achieved BSA ≤ 1% at week 12 was significantly higher than that of patients using other biologics. - **Acceptable Response**: In the PSoHO study, the proportion of patients using anti - IL - 17A biologics who achieved BSA ≤ 3% or BSA improvement ≥ 75% at week 12 was significantly higher than that of patients using other biologics. ### Conclusions - **Main Findings**: Whether in clinical trials or real - world studies, the proportion of patients with plaque psoriasis treated with IXE who achieve the NPF goals and acceptable responses at week 12 is significantly higher than that of patients using other biologics. - **Clinical Significance**: IXE shows better efficacy in the treatment of moderate - to - severe plaque psoriasis, which helps patients reach skin clearance or near - clearance more quickly, thereby improving the quality of life of patients. ### Discussion - **T2T Strategy**: The NPF's T2T strategy provides clear goals for the treatment of plaque psoriasis, aiming to reduce the disease burden and improve patient prognosis. The research results of this paper support the advantages of IXE in achieving these goals, especially in the early treatment stage. - **Future Directions**: Future research can further explore the long - term treatment effects of IXE and its performance in different subgroups of patients, such as biologic - naïve and biologic - experienced patients.

Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies

Efficacy and Safety of Ixekizumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis: 60-Week Results from a Phase 3 Study

Higher rates of skin clearance and efficacy in challenging body areas are associated with better health-related quality of life following ixekizumab maintenance treatment in pediatric patients with plaque psoriasis

Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

Ixekizumab treatment in patients with moderate-to-severe plaque psoriasis in a real-world clinical setting

Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60

Ixekizumab (Interleukin 17A Antagonist): 12-week Efficacy and Safety Outcomes in Real-world Clinical Practice

Efficacy and Safety Analysis in Chinese Patients with Moderate-to-Severe Psoriasis from a Phase 3 Trial: Impact of Treatment Withdrawal and Retreatment of Ixekizumab

Effectiveness of ixekizumab for the treatment of moderate‐to‐severe plaque psoriasis with involvement of difficult‐to‐treat areas: A 52‐week multicenter retrospective study

From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis

Outcomes for Psoriasis by Self-Identified Racial Groups in Ixekizumab Clinical Trials: A Pooled Analysis

Pharmacokinetics, Safety, and Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 1, Single- and Multiple-Dose Study.

Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)

Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis

Bimekizumab for the Treatment of Moderate-to-severe Plaque Psoriasis: a Meta-Analysis of Randomized Clinical Trials

Comparation of time-course, dose-effect, influencing factors and adverse events of biologics in the treatment of adults with moderate to severe plaque psoriasis

Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients With Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results From the Randomized SPIRIT-H2H Trial

Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity

Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry

Ixekizumab Demonstrates Consistent Efficacy Versus Adalimumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Psoriatic Arthritis Patients Regardless of Psoriasis Severity: 52-Week Post Hoc Results from SPIRIT-H2H

Comparative 12‐week effectiveness and safety outcomes of biologic agents ustekinumab, secukinumab and ixekizumab for the treatment of plaque psoriasis: a real‐world multicenter retrospective study